论文部分内容阅读
目的分析联合应用厄贝沙坦(IBT)及美托洛尔(MTR)对慢性充血性心衰(CHF)的疗效情况。方法按照入院顺序奇偶法将86例CHF患者分为实验组及对照组,各43例。实验组联合应用IBT及MTR,对照组单用MTR,对比两组临床疗效。结果治疗16周后,实验组总有效率为95.3%,显著高于对照组(P<0.05);实验组左室舒张末内径(LVEDD)、左室收缩末内径(LVESD)、左室射血分数(LVEF)均优于对照组(P<0.05)。结论联合应用厄贝沙坦及美托洛尔治疗CHF临床疗效更加显著。
Objective To analyze the curative effect of combined use of irbesartan (IBT) and metoprolol (MTR) on chronic congestive heart failure (CHF). Methods According to the order of parity method, 86 cases of CHF patients were divided into experimental group and control group, 43 cases in each. The experimental group combined with IBT and MTR, the control group alone MTR, compared the clinical efficacy of the two groups. Results After 16 weeks of treatment, the total effective rate in the experimental group was 95.3%, significantly higher than that in the control group (P <0.05). The left ventricular end diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD) Score (LVEF) were better than the control group (P <0.05). Conclusion The combination of irbesartan and metoprolol in the treatment of CHF has a more significant clinical effect.